EXPERIENCE A NEW PERSPECTIVE IN TUMOR CONTROL
AFINITOR® (everolimus) is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumors (NET) of gastrointestinal or lung origin in adults with progressive disease; and for the treatment of unresectable or metastatic, well- or moderately-differentiated NET of pancreatic origin in adults with progressive disease.
GI, gastrointestinal; NET, neuroendocrine tumor(s); PFS, progression-free survival; pNET, pancreatic neuroendocrine tumor(s).
- AFINITOR [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; August 2017.
- Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977.
- Yao JC, Shah MH, Ito T, et al; for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
- Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906-3913.